Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis

被引：0
|
作者：
Farrell, James [1 ]
Bertin, Nicolas [2 ]
Fischer, Claire [3 ]
Gauthier, Aline [4 ]
机构：
[1] Bristol Myers Squibb, Dublin, Ireland
[2] Amaris, Hlth Econ & Market Access, Paris, France
[3] Amaris, Hlth Econ & Market Access, Montreal, PQ, Canada
[4] Amaris, Hlth Econ & Market Access, Barcelona, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-244
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [11] POMALIDOMIDE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): EXPERIENCE CENTER
    Cuesta Garcia, A.
    HAEMATOLOGICA, 2015, 100 : 104 - 104
  • [12] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
    Matsue, Kosei
    Iwasaki, Hiromi
    Chou, Takaaki
    Tobinai, Kensei
    Sunami, Kazutaka
    Ogawa, Yoshiaki
    Kurihara, Mari
    Midorikawa, Shuichi
    Zaki, Mohamed
    Doerr, Thomas
    Iida, Shinsuke
    CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
  • [13] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    Blood Cancer Journal, 8
  • [14] Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Takafumi Ide
    Mayu Osawa
    Kinjal Sanghavi
    Heather E. Vezina
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 129 - 140
  • [15] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Sivaraj, Dharshan
    Green, Michael M.
    Kang, Yubin
    Long, Gwynn D.
    Rizzieri, David A.
    Li, Zhiguo
    Garrett, Anderson H.
    McIntyre, Jackie L.
    Chao, Nelson J.
    Gasparetto, Cristina
    BLOOD CANCER JOURNAL, 2018, 8
  • [16] Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis
    Chen, Runzhe
    Wang, Yujie
    Luan, Chengxin
    Gao, Chong
    Zhang, Xiaoping
    Chen, Baoan
    JOURNAL OF CANCER, 2017, 8 (10): : 1801 - 1808
  • [17] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Leleu, Xavier
    Tsao, L. Claire
    Westland, Christopher
    Singhal, Anil K.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
  • [18] Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    DerSarkissian, Maral
    Cranmer, Holly
    Dabora, Jonathan
    Bocharova, Iryna
    Cherepanov, Dasha
    Cheng, Mu
    Bhak, Rachel H.
    Duh, Mei Sheng
    HEMATOLOGY, 2023, 28 (01)
  • [19] Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials.
    Paul, Barry
    Robinson, Myra M.
    Robinson, Jordan
    Ndiaye, Ami
    Bhutani, Manisha
    Voorhees, Peter Michael
    Symanowski, James Thomas
    Friend, Reed N.
    Pineda-Roman, Mauricio
    Usmani, Saad Zafar
    Atrash, Shebli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [20] A SINGLE CENTER EXPERIENCE OF POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
    Duran, M.
    Tombuloglu, M.
    Tobu, M.
    Vural, F.
    Sahin, F.
    Patir, P.
    Uysal, A.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S18 - S19
12345